United States Patent 7,750,029: Claim Scope, Scope Limiters, and US Landscape for (R)-Anilide Anti-Overactive-Bladder Use
US Drug Patent 7,750,029 claims methods of treating overactive bladder (OAB) with a single defined active ingredient: (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide (and salts/free base). The enforceable scope is tightly bounded by (i) the active-ingredient identity, (ii) the disease target being OAB, and (iii) an express exclusion: the treated subject “is not suffering from diabetes.” Dependent claims narrow further to OAB subtypes linked to benign prostatic hyperplasia (BPH) and symptom phenotypes (urgency, urge incontinence, pollakiuria). The patent’s practical position in the US landscape hinges on how other families cover alternative actives, alternative enantiomers, alternative salt forms, different diabetes-related exclusions, and non-method uses (composition, dosing regimens, device combinations).
What does claim 1 actually cover?
Core independent claim (claim 1) recites a method of treatment:
- Target condition: “overactive bladder”
- Treatment type: administering a “pharmaceutically effective amount”
- Active ingredient: “(R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a salt thereof”
- Key patient qualifier (scope limiter): “wherein the subject is not suffering from diabetes”
Claim 1 is drafted as a classic use-of-a-specific-active method claim with an additional negative limitation on the subject condition.
Scope implications of the diabetes exclusion
The phrase “subject is not suffering from diabetes” functions as a conditional restriction. Practically, it can drive claim interpretation toward:
- denial of infringement where the treated subject has diabetes (diagnosed or otherwise “suffering from diabetes”), and
- potential boundary fights over what counts as “diabetes” (type, diagnosis status, prediabetes vs diabetes, controlled vs uncontrolled), depending on claim construction and the evidentiary record.
From an enforcement perspective, it adds a factual element that can be used to narrow the reachable patient population. From a formulation/labeling perspective, it can complicate attempts to market an OAB therapy with broader use including diabetic patients.
How does claim 6 broaden or change the active-ingredient limitation?
Independent claim (claim 6) is structurally parallel to claim 1, but with a critical difference:
- Active ingredient restriction: the “free base form” (no salts in claim 6)
- Key qualifier remains: “wherein the subject is not suffering from diabetes”
So, claim 1 covers anilide or salts; claim 6 covers the anilide in free base form. These claims can coexist without redundancy because different commercialization strategies can map to different claim sets:
- A product marketed and practiced strictly as a salt can land more cleanly in claim 1’s “or a salt thereof” phrasing while claim 6 is not the cleanest fit.
- A product marketed as a free base maps more directly to claim 6, while claim 1 still remains potentially relevant because it includes “free base” implicitly only if the “anilide” in the claim is construed to include free base. The claim language says “anilide or a salt thereof” in claim 1, which strongly suggests free base is encompassed under “anilide.”
Do dependent claims narrow the clinical phenotype?
Yes. Both claim families (claims 1-5 and claims 6-10) include dependent narrowing to OAB etiologies and symptom expressions.
Claim 2 / 7: OAB “result of benign prostatic hyperplasia”
- Claim 2 (dependent of claim 1): OAB is “a result of benign prostatic hyperplasia.”
- Claim 7 (dependent of claim 6): same limitation.
This narrows infringement to clinical contexts where the OAB is attributable to BPH. In real-world practice, this maps to patient subsets labeled as BPH-related LUTS or BPH-associated OAB.
Claim 3 / 8: urinary urgency
- OAB patient has “urinary urgency.”
Claim 4 / 9: urge incontinence
- OAB patient has “urinary urge incontinence.”
Claim 5 / 10: pollakiuria
- OAB patient has “pollakiuria.”
These symptom-based dependent claims provide layered coverage. If a generic or competitor product is prescribed for OAB patients with any one of these phenotypes, a claim strategy can focus on which phenotype best matches how clinical labels and study protocols define the treated endpoints.
Is “human” status a meaningful limitation?
Claims 11 and 12 add:
- Claim 11: subject is human (dependent of claim 1)
- Claim 12: subject is human (dependent of claim 6)
This is standard and generally not a major differentiator in enforcement for a US method-of-treatment patent covering clinical administration to patients.
Claim chart style summary (what must be proven)
Independent claim 1 elements
- Treating “overactive bladder”
- Administering pharmaceutically effective amount
- Active ingredient identity: (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a salt
- Subject is not suffering from diabetes
Dependent claim 2-5 add-on limitations (optional)
- BPH-related OAB (claim 2)
- urgency (claim 3)
- urge incontinence (claim 4)
- pollakiuria (claim 5)
Independent claim 6 elements
Same as claim 1, but element 3 is narrowed to:
- active ingredient is in free base form (no salts)
Then dependent claim 7-10 mirror claim 2-5.
How do the claims position the active ingredient in the broader OAB space?
OAB methods in the US frequently overlap among several therapeutic classes: antimuscarinics, beta-3 agonists, botulinum toxin regimens, and newer modalities. US patentability and enforceability usually split across:
- Composition-of-matter patents (active itself, crystalline forms, salts, polymorphs)
- Method-of-use patents (specific indications, specific patient subsets, dosing regimens)
- Process patents (manufacturing)
US 7,750,029 is a method-of-treatment patent. Its enforceable boundary is therefore most vulnerable to:
- “non-overlapping” active ingredients (if a competitor uses a different drug)
- “non-overlapping” treatment context (if competitor’s labeled or prescribed population includes diabetics despite your claim’s exclusion)
- patient subset differences (BPH-attributable vs non-BPH OAB)
- active form differences (salt vs free base), depending on which claim is asserted
Practical claim scope: what does it capture in the clinic?
Below is the most operational interpretation for patient targeting, based strictly on claim text.
Covered OAB treatment scenarios (claims 1 and 6 baseline)
- Any OAB patient who is not suffering from diabetes
- Treated with the specific (R)-anilide or (for claim 6) the free base form
- Under standard “pharmaceutically effective amount” administration
Additional covered clinical scenarios (dependent claims)
- OAB due to BPH (claims 2 and 7)
- OAB presenting with urgency, urge incontinence, and/or pollakiuria (claims 3-5 and 8-10)
Scenarios that can fall outside
- Any treated subject who is “suffering from diabetes” (as a factual limitation)
- Treatments that use different active ingredients or different stereochemistry (the claims specify (R))
- Treatments outside OAB (the claims require OAB)
- Purely non-method commercialization (e.g., only providing a device, or only making a composition without administration)
Patent landscape: where 7,750,029 fits and what it leaves open
Given only the claim text provided, landscape mapping can be performed at the level of design-around vectors and likely adjacent patent families that commonly exist for a developed OAB drug.
Design-around vectors against method-of-treatment claims
A competitor can often avoid infringement by shifting at least one required claim element:
- Switch active ingredient: use another OAB therapeutic with no overlap in the claimed chemical structure.
- Change stereochemistry: avoid using the (R)-enantiomer (if a different enantiomer is used, the “(R)” limitation becomes a key barrier).
- Alter salt vs free base strategy:
- If a product is exclusively a salt form, claim 6 is less clean; claim 1 still reaches “or a salt thereof.”
- If a product is exclusively free base, claim 6 is the cleanest target; claim 1 likely remains relevant.
- Include diabetics in the treated population:
- Because the claims require “subject is not suffering from diabetes,” a practice pattern that includes diabetic patients can help avoid the specific patient-subset element (subject to claim construction and evidence).
- Avoid BPH attribution if targeting BPH-driven studies:
- Dependent claim 2/7 specifically require OAB “result of benign prostatic hyperplasia.” If a labeled indication is “OAB” without BPH attribution, those dependents may be harder to map.
What 7,750,029 does not cover (based on claim text)
The claim set does not, on its face:
- claim formulation/composition (only administration is claimed)
- claim specific dosing regimens (no dose, frequency, or duration is specified)
- claim specific study endpoints or measures (no I-PSS, OAB-q, pad weight, micturition frequency thresholds)
- claim device-based delivery or combination therapy (no combination components are claimed)
That leaves open the possibility that other patents in the same technical area cover dosing, crystalline forms, salts, or manufacturing processes. Conversely, it also means competitors may be free to develop alternative administration regimens or combination approaches that do not match the claimed administration method elements.
Risk map by competitor product strategy
1) Generic/authorized product using the same (R)-anilide
- High risk: method-of-use coverage is direct.
- The diabetes exclusion is the key hinge: risk increases if clinical practice and labeling target a “not diabetic” subset.
2) Product using the same core chemical but different salt form
- Claim 1 still covers “anilide or a salt thereof.”
- Only claim 6 (free base) can be avoided by using exclusively salts, but claim 1 remains.
3) Product using the same chemical but as a different enantiomer
- Lower risk: “(R)” is explicit. A different enantiomer should not meet the active-ingredient identity requirement.
4) Product using a different active ingredient
- Lower risk on this patent: claim 1 and 6 require this exact active structure.
5) Product with diabetic-labeled use for OAB
- Potentially lower risk against the diabetes-exclusion element, but enforceability depends on how courts construe “suffering from diabetes” and on proof.
Key takeaways on scope and likely enforcement posture
- The patent targets a single active ingredient identity: (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide.
- Claim coverage is split by form: claim 1 covers “anilide or salts,” claim 6 covers “free base form.”
- The most consequential limiter is the patient restriction: “subject is not suffering from diabetes.” This creates an additional infringement element that can narrow the reachable population.
- Dependent claims narrow by etiology and symptoms: BPH attribution and urgency/urge incontinence/pollakiuria.
Key Takeaways
- US 7,750,029 is a method-of-treatment patent for OAB with a narrowly defined (R)-anilide active ingredient.
- The diabetes exclusion is a central scope limiter and can materially affect infringement analysis and labeling strategy.
- Dependent claims add BPH attribution and symptom phenotypes (urgency, urge incontinence, pollakiuria).
- The claim set does not, from the provided language, lock down dosing, composition, or combination regimens, leaving other claim domains to other patent families if they exist.
FAQs
1) Does US 7,750,029 cover treatment of OAB patients with diabetes?
No, the claims require that “the subject is not suffering from diabetes,” which is a limitation embedded in both independent claims.
2) Is a salt form covered?
Yes for claim 1 because it covers “anilide or a salt thereof.” Claim 6 is limited to the “free base form.”
3) What if a product is only administered to humans?
That satisfies claims 11 and 12’s “subject is human” limitation, since those claims already specify human subjects.
4) Do dependent claims require BPH-related OAB?
Only dependent claims 2 and 7. The independent claims cover OAB broadly (subject to the diabetes exclusion and the active ingredient).
5) Can an entrant avoid this patent by using a different OAB drug class?
Yes, if the active ingredient is different from the claimed (R)-anilide, it would not meet the active-ingredient element in claims 1 or 6.
References
[1] US Patent 7,750,029, claims 1-12 (as provided in the prompt).
